ABSTRACT
Children presenting with bleeding symptoms pose a diagnostic challenge. The evaluation should include a comprehensive medical and bleeding history, detailed family history, a physical examination, and selected laboratory tests. Evaluation of the bleeding history should include an objective quantitation of the bleeding symptoms, followed by objective quantitation of the family members' bleeding symptoms. If a bleeding disorder is suspected, based on personal and/or family bleeding history, specific laboratory testing is needed for attaining a diagnosis. The screening tests for coagulation factor deficiencies are considered reliable, routinely available, and easy to perform. However, for primary hemostatic defects, the various screening tests have not yet proven to be reliable and thus referral for a specialized hematology consultation and specific laboratory testing are needed. Perhaps a Bayes theorem approach, combining the personal and family bleeding history with the results of a screening test for a primary hemostatic defect would prove to be useful in the identification of those children who will most benefit from specific laboratory testing.
KEYWORDS
Bleeding disorder - assessment - children - bleeding questionnaires - laboratory screening
REFERENCES
-
1
Werner E J, Broxson E H, Tucker E L, Giroux D S, Shults J, Abshire T C.
Prevalence of von Willebrand disease in children: a multiethnic study.
J Pediatr.
1993;
123
(6)
893-898
-
2
Bowman M, Hopman W M, Rapson D, Lillicrap D, James P.
The prevalence of symptomatic von Willebrand disease in primary care practice.
J Thromb Haemost.
2010;
8
(1)
213-216
-
3
Bowman M, Hopman W M, Rapson D, Lillicrap D, Silva M, James P.
A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population.
Pediatr Blood Cancer.
2010;
55
(1)
171-173
-
4
Peyvandi F, Cattaneo M, Inbal A, De Moerloose P, Spreafico M.
Rare bleeding disorders.
Haemophilia.
2008;
14
(Suppl 3)
202-210
-
5
Salles I I, Feys H B, Iserbyt B F, De Meyer S F, Vanhoorelbeke K, Deckmyn H.
Inherited traits affecting platelet function.
Blood Rev.
2008;
22
(3)
155-172
-
6
Nurden P, Nurden A T.
Congenital disorders associated with platelet dysfunctions.
Thromb Haemost.
2008;
99
(2)
253-263
-
7
Hayward C P, Rao A K, Cattaneo M.
Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment.
Haemophilia.
2006;
12
(Suppl 3)
128-136
-
8
Blanchette V S, Bolton-Maggs P.
Childhood immune thrombocytopenic purpura: diagnosis and management.
Pediatr Clin North Am.
2008;
55
(2)
393-420, ix
-
9
Cines D B, Bussel J B, McMillan R B, Zehnder J L.
Congenital and acquired thrombocytopenia.
Hematology (Am Soc Hematol Educ Program).
2004;
390-406
-
10
Anwar R, Minford A, Gallivan L, Trinh C H, Markham A F.
Delayed umbilical bleeding—a presenting feature for factor XIII deficiency: clinical features, genetics, and management.
Pediatrics.
2002;
109
(2)
E32
-
11 Carcao M D, Blanchette V S. Work-up of a bleeding child. In: Lee C, Berntorp E, Hoots K, eds. Textbook of Hemophilia. 2nd ed. West, Sussex, UK: Blackwell; 2010: 118-126
-
12
Seligsohn U.
Factor XI deficiency in humans.
J Thromb Haemost.
2009;
7
(Suppl 1)
84-87
-
13
Simon D, Kunicki T, Nugent D.
Platelet function defects.
Haemophilia.
2008;
14
(6)
1240-1249
-
14
Nosek-Cenkowska B, Cheang M S, Pizzi N J, Israels E D, Gerrard J M.
Bleeding/bruising symptomatology in children with and without bleeding disorders.
Thromb Haemost.
1991;
65
(3)
237-241
-
15
Lillicrap D, Nair S C, Srivastava A, Rodeghiero F, Pabinger I, Federici A B.
Laboratory issues in bleeding disorders.
Haemophilia.
2006;
12
(Suppl 3)
68-75
-
16
Rodeghiero F, Kadir R A, Tosetto A, James P D.
Relevance of quantitative assessment of bleeding in haemorrhagic disorders.
Haemophilia.
2008;
14
(Suppl 3)
68-75
-
17
Rodeghiero F, Castaman G, Tosetto A et al..
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study.
J Thromb Haemost.
2005;
3
(12)
2619-2626
-
18
Tosetto A, Rodeghiero F, Castaman G et al..
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).
J Thromb Haemost.
2006;
4
(4)
766-773
-
19
Bowman M, Riddel J, Rand M L, Tosetto A, Silva M, James P D.
Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire.
J Thromb Haemost.
2009;
7
(8)
1418-1421
-
20
Biss T T, Blanchette V S, Clark D S et al..
Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire.
J Thromb Haemost.
2010;
8
(5)
950-956
-
21
Biss T T, Blanchette V S, Clark D S, Wakefield C D, James P D, Rand M L.
Use of a quantitative pediatric bleeding questionnaire to assess mucocutaneous bleeding symptoms in children with a platelet function disorder.
J Thromb Haemost.
2010;
8
(6)
1416-1419
-
22
Tosetto A, Castaman G, Rodeghiero F.
Bleeding scores in inherited bleeding disorders: clinical or research tools?.
Haemophilia.
2008;
14
(3)
415-422
-
23 Clinical and Laboratory Standards Institute .Platelet Function Testing By Aggregometry; Approved Guideline. 2008 Vol. 28, No. 31
-
24
Cariappa R, Wilhite T R, Parvin C A, Luchtman-Jones L.
Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems.
J Pediatr Hematol Oncol.
2003;
25
(6)
474-479
-
25
Schlammadinger A, Kerenyi A, Muszbek L, Boda Z.
Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease.
Thromb Haemost.
2000;
84
(1)
88-92
-
26
Posan E, McBane R D, Grill D E, Motsko C L, Nichols W L.
Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice.
Thromb Haemost.
2003;
90
(3)
483-490
-
27
Quiroga T, Goycoolea M, Muñoz B et al..
Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients.
J Thromb Haemost.
2004;
2
(6)
892-898
-
28
Kundu S K, Heilmann E J, Sio R, Garcia C, Davidson R M, Ostgaard R A.
Description of an in vitro platelet function analyzer—PFA-100.
Semin Thromb Hemost.
1995;
21
(Suppl 2)
106-112
-
29
Favaloro E J, Facey D, Henniker A.
Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders.
Am J Hematol.
1999;
62
(3)
165-174
-
30
Francis J, Francis D, Larson L, Helms E, Garcia M.
Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice?.
Platelets.
1999;
10
(2-3)
132-136
-
31
Carcao M D, Blanchette V S, Dean J A et al..
The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children.
Br J Haematol.
1998;
101
(1)
70-73
-
32
Karger R, Donner-Banzhoff N, Müller H H, Kretschmer V, Hunink M.
Diagnostic performance of the platelet function analyzer (PFA-100) for the detection of disorders of primary haemostasis in patients with a bleeding history-a systematic review and meta-analysis.
Platelets.
2007;
18
(4)
249-260
-
33
Hayward C P, Harrison P, Cattaneo M, Ortel T L, Rao A K.
Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.
J Thromb Haemost.
2006;
4
312-319
-
34
Kratzer M AA, Kretschmer V.
Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function—a rebuttal.
J Thromb Haemost.
2006;
4
1429-1431
-
35
Koscielny J, Kiesewetter H, von Tempelhoff G F.
More on: platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.
J Thromb Haemost.
2006;
4
(6)
1426-1427, discussion 1428–1434
-
36
Varon D, Dardik R, Shenkman B et al..
A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions.
Thromb Res.
1997;
85
(4)
283-294
-
37
Revel-Vilk S, Varon D, Shai E et al..
Evaluation of children with a suspected bleeding disorder applying the Impact-R [Cone And Plate(Let) Analyzer].
J Thromb Haemost.
2009;
7
1990-1996
-
38
Quiroga T, Goycoolea M, Giesen P L et al..
Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages.
Pathophysiol Haemost Thromb.
2003;
33
(1)
30-35
-
39
Eugster M, Reinhart W H.
The influence of the haematocrit on primary haemostasis in vitro.
Thromb Haemost.
2005;
94
(6)
1213-1218
-
40
Carcao M D, Blanchette V S, Stephens D et al..
Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA-100).
Br J Haematol.
2002;
117
(4)
961-964
-
41
Tosetto A, Castaman G, Rodeghiero F.
Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach.
Blood.
2008;
111
(8)
3998-4003
-
42
Acharya S S, Coughlin A, Dimichele D M. North American Rare Bleeding Disorder Study Group .
Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias.
J Thromb Haemost.
2004;
2
(2)
248-256
-
43
Bernardi F, Dolce A, Pinotti M International Factor VII Deficiency Study Group et al.
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B.
J Thromb Haemost.
2009;
7
(5)
774-779
-
44
Plug I, Mauser-Bunschoten E P, Bröcker-Vriends A H et al..
Bleeding in carriers of hemophilia.
Blood.
2006;
108
(1)
52-56
-
45
Hsieh L, Nugent D.
Factor XIII deficiency.
Haemophilia.
2008;
14
(6)
1190-1200
-
46
Spreafico M, Peyvandi F.
Combined factor V and factor VIII deficiency.
Semin Thromb Hemost.
2009;
35
(4)
390-399
-
47
Nichols W L, Hultin M B, James A H et al..
von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
Haemophilia.
2008;
14
(2)
171-232
-
48
Nurden A T, Nurden P.
The gray platelet syndrome: clinical spectrum of the disease.
Blood Rev.
2007;
21
(1)
21-36
-
49
Althaus K, Greinacher A.
MYH9-related platelet disorders.
Semin Thromb Hemost.
2009;
35
(2)
189-203
-
50
Rao A K.
Inherited defects in platelet signaling mechanisms.
J Thromb Haemost.
2003;
1
(4)
671-681
-
51
Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M.
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome.
Blood.
2009;
113
(25)
6288-6295
-
52
Albert M H, Bittner T C, Nonoyama S et al..
X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options.
Blood.
2010;
115
(16)
3231-3238
-
53
Owen C.
Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML).
Leuk Res.
2010;
34
(2)
141-142
-
54
Ballmaier M, Germeshausen M.
Advances in the understanding of congenital amegakaryocytic thrombocytopenia.
Br J Haematol.
2009;
146
(1)
3-16
-
55
Geddis A E, Kaushansky K.
Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production.
Curr Opin Pediatr.
2004;
16
(1)
15-22
-
56 Toriello H V. Thrombocytopenia absent radius syndrome. In: Genereviews [Internet]. Seattle, WA: University of Washington; 2009
-
57
Pham A, Wang J.
Bernard-Soulier syndrome: an inherited platelet disorder.
Arch Pathol Lab Med.
2007;
131
(12)
1834-1836
-
58
Pallotta R, Evangelista V, Margaglione M, Bucci I, Saponari A.
Macrothrombocytopenia in velocardiofacial syndrome.
J Thromb Haemost.
2005;
3
(3)
601-603
-
59
Favaloro E J.
Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?.
Semin Thromb Hemost.
2008;
34
(1)
113-127
-
60
Behrens W E.
Mediterranean macrothrombocytopenia.
Blood.
1975;
46
(2)
199-208
-
61 Kacena M A, Kirk J, Chou S T, Weiss M J, Raskind W H. GATA1-related X-linked cytopenia. In: Pagon R A, Bird T D, Dolan C R, Stephens K, eds. GeneReviews [Internet]. University of Washington, Seattle, 2006
-
62
Gunay-Aygun M, Zivony-Elboum Y, Gumruk F et al..
Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.
Blood.
2010;
116
(23)
4990-5001
Shoshana Revel-VilkM.D. M.Sc.
Department of Pediatric Hematology/Oncology, Hadassah Hebrew University Hospital
POB 12000, Jerusalem 91200, Israel
Email: shoshanav@hadassah.org.il
